Updated:
AliveCor
AliveCor builds AI-powered ECG devices and software for consumer and clinical cardiac monitoring.
AliveCor
AliveCor develops cardiac monitoring technology centered on its Kardia line of FDA-cleared ECG devices and accompanying software. The company's products allow users to record medical-grade electrocardiograms outside clinical settings, with AI-driven analysis for arrhythmia detection. The firm's technology stack spans hardware (KardiaMobile, KardiaMobile 6L, Kardia 12L) and software (KardiaCare, KardiaComplete). AliveCor targets patients, providers, payers, biopharma companies, and health systems, generating data streams for clinical trials and remote monitoring. The company reports partnerships with life science organizations, though specific deal terms remain undisclosed. AliveCor operates from multiple US offices—Alexandria, Scottsdale, Mountain View, San Francisco, and Lake Forest—reflecting functions across engineering, regulatory, sales, and customer support. The company raised over $130 million in venture funding from investors including Khosla Ventures and the Mayo Clinic, but its current corporate structure or ownership is not specified. AliveCor differentiates through an integrated hardware-software-data platform under FDA oversight, a regulatory posture that raises barriers for pure-software competitors in cardiac monitoring. The company also holds patents on AI-based ECG interpretation, creating intellectual property moats in a space where clinical validation and clearance cycles are lengthy.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Alexandria
Corporate office
Alexandria, VA, United States
Additional offices
Scottsdale · Mountain View · San Francisco · Lake Forest
Sector focus
Frequently asked questions
What are AliveCor's main products?
AliveCor offers the Kardia line of FDA-cleared ECG devices, including KardiaMobile, KardiaMobile 6L, and Kardia 12L. These are paired with software platforms like KardiaCare and KardiaComplete for AI-driven rhythm analysis and remote monitoring (per the firm's website).
How does AliveCor generate revenue?
AliveCor sells ECG hardware directly to consumers and healthcare providers, and also licenses its technology and data platform to life sciences companies for clinical trials and research (per the firm's website). Specific revenue figures or segment breakdowns are not publicly disclosed.
Is AliveCor a venture-backed company?
Yes, AliveCor has raised over $130 million from investors including Khosla Ventures and the Mayo Clinic (per Crunchbase, 2023). Its current ownership structure is not specified.
What regulatory clearances does AliveCor hold?
AliveCor's Kardia devices are FDA-cleared for detecting atrial fibrillation and other arrhythmias. The Kardia 12L device received FDA clearance in 2021 (per the firm's website).
Does AliveCor have a direct-to-consumer offering?
Yes, AliveCor sells KardiaMobile and KardiaMobile 6L directly to consumers via its website and retail partners. Users can subscribe to KardiaCare for enhanced AI analysis and physician review (per the firm's website).
Who competes with AliveCor in cardiac monitoring?
AliveCor competes with Apple's ECG feature on Apple Watch, as well as with other medical-device companies like iRhythm Technologies and Bardy Diagnostics.
What is the Kardia 12L Two-Week Trial?
The Kardia 12L Two-Week Trial offers eligible US healthcare providers the chance to try AliveCor's 12-lead ECG device for two weeks at no cost, promoting clinical evaluation (per the firm's website).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: